Alnylam Pharmaceuticals
ALNY
487 hedge funds and large institutions have $28.3B invested in Alnylam Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 177 increasing their positions, 149 reducing their positions, and 85 closing their positions.
27% more funds holding in top 10
Funds holding in top 10: 11 → 14 (+3)
26% more call options, than puts
Call options by funds: $401M | Put options by funds: $318M
19% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 149
6% more capital invested
Capital invested by funds: $26.7B → $28.3B (+$1.64B)
1% less first-time investments, than exits
New positions opened: 84 | Existing positions closed: 85
2% less funds holding
Funds holding: 497 → 487 (-10)
14.14% less ownership
Funds ownership: 111.13% → 96.98% (-14%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
+$521M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$177M |
| 3 |
BlackRock
New York
|
+$175M |
| 4 |
JP Morgan Chase
New York
|
+$124M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$120M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$3.41B |
| 2 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$121M |
| 3 |
Amundi
Paris,
France
|
-$113M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$97.1M |
| 5 |
Dodge & Cox
San Francisco,
California
|
-$63.7M |
ALNY Hedge Fund Activity: Q4 2022 in Review
487 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2022, worth a combined $28.3B — up 6.1% from $26.7B a quarter earlier.
Sellers outnumbered buyers: 85 funds closed out of ALNY and 84 opened new positions — a net loss of 1 holder — while 149 trimmed existing stakes and 177 added.
The largest buyer was Capital World Investors, adding an estimated $521M. The largest seller was Nuveen, cutting an estimated $3.41B.
- 487 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2022, down from 497 in Q3 2022.
- Funds reported $28.3B of Alnylam Pharmaceuticals stock for Q4 2022, up 6.1% quarter-over-quarter.
- 84 funds opened new Alnylam Pharmaceuticals positions in Q4 2022 and 85 closed out, a net change of -1 holder.
- The largest Alnylam Pharmaceuticals buyer in Q4 2022 was Capital World Investors, an estimated $521M added.
- The largest Alnylam Pharmaceuticals seller in Q4 2022 was Nuveen, an estimated $3.41B sold.
Based on aggregated 13F filings for Q4 2022.